Liothyronine
Back to searchMolecule Structure
Scientific Name
Liothyronine
Description of the Drug
Liothyronine is a thyroid hormone replacement therapy used to treat hypothyroidism, to suppress TSH, and to help in the diagnosis of hyperthyroidism.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00279
http://www.drugbank.ca/drugs/DB00279
Brand Name(s)
Cytomel, Tertroxin
Company Owner(s)
Parke Davis Div Warner Lambert Co, Teva Pharmaceuticals Usa Inc, King Pharmaceuticals Research And Development Llc, Sigmapharm Laboratories Llc, Par Sterile Products Llc, Sun Pharmaceutical Industries Ltd, Mayne Pharma Inc, Watson Laboratories Inc, Mylan Pharmaceuticals Inc, Xgen Pharmaceuticals Djb Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Thyroid hormone receptor | PROTEIN COMPLEX | AGONIST | CHEMBL2111462 |
Clinical Trial(s)
Unichem Links
Atlas | triiodothyronine | ||||||||||||
SureChEMBL | SCHEMBL8300 | ||||||||||||
PharmGKB | PA164778866 | ||||||||||||
Human Metabolome Database | HMDB0000265 | ||||||||||||
DrugBank | DB00279 | ||||||||||||
PubChem: Thomson Pharma | 14936961 | 14964754 | |||||||||||
PubChem | 5920 | 7048703 | |||||||||||
NMRShiftDB | 60020610 | ||||||||||||
LINCS | LSM-3991 | ||||||||||||
Nikkaji | J85.948F | ||||||||||||
PDBe | T3 | ||||||||||||
BindingDB | 18860 | ||||||||||||
EPA CompTox Dashboard | DTXSID8023216 | ||||||||||||
DrugCentral | 1585 | ||||||||||||
Metabolights | MTBLC533015 | MTBLC18258 | |||||||||||
Brenda | 220663 | 2069 | 24561 | 132769 | 62262 | 5480 | 12575 | 5223 | 66993 | 144156 | 101783 | 9030 | 10918 |
Rhea | 533015 | ||||||||||||
ChemicalBook | CB8221269 | ||||||||||||
Guide to Pharmacology | 2634 | ||||||||||||
rxnorm | CYTOMEL | LIOTHYRONINE | TRIOSTAT | LIOTHYRONINE SODIUM | |||||||||
KEGG Ligand | C02465 | ||||||||||||
ChEBI | 18258 | 533015 | |||||||||||
ZINC | ZINC000003830999 |